Suppr超能文献

同种异体脂肪来源干细胞治疗犬类风湿关节炎的长期疗效观察。

Long-term treatment of allogeneic adipose-derived stem cells in a dog with rheumatoid arthritis.

机构信息

Department of Veterinary Pathology, College of Veterinary Medicine, Gyeongsang National University, Jinju 52828, Korea.

Cardiovascular Product Evaluation Center, College of Medicine, Yonsei University, Seoul 03722, Korea.

出版信息

J Vet Sci. 2022 Jul;23(4):e61. doi: 10.4142/jvs.22069.

Abstract

BACKGROUND

Although there are growing demands for stem cell-based therapy for companion animals in various diseases, a few clinical trials have been reported. Moreover, most of them are the results from only one or a few times of stem cell injection.

OBJECTIVES

The aim of this study is to describe a long-term treatment with allogeneic adipose-derived stem cells (ASCs) in a dog with rheumatoid arthritis (RA), which is a rare canine disease.

METHODS

The dog with RA received intravascular injection of allogeneic ASCs derived from two healthy donors once a month for 11 months. To assess therapeutic effects of ASCs, orthopedic examination and clinical evaluation was performed. Cytokines of tumor necrosis factor-α and interleukin-6 in the plasma were measured using ELISA analysis.

RESULTS

Despite this repeated and long-term administration of allogeneic ASCs, there were no side effects such as immunorejection responses or cell toxicity. The orthopedic examination score for the dog decreased after ASCs treatment, and the clinical condition of the dog and owner's satisfaction were very good.

CONCLUSIONS

Although ASCs has been suggested as one of the options for RA treatment because of its anti-inflammatory and immunosuppressive functions, it has never been used to treat RA in dogs. The present report describes a case of canine RA treated with allogeneic ASCs for long-term in which the dog showed clinical improvement without adverse effects.

摘要

背景

尽管对各种疾病的伴侣动物的基于干细胞的治疗的需求不断增长,但仅报道了少数临床试验。此外,它们中的大多数仅来自一次或几次干细胞注射的结果。

目的

本研究旨在描述患有类风湿关节炎(RA)的犬的同种异体脂肪来源干细胞(ASCs)的长期治疗,这是一种罕见的犬病。

方法

患有 RA 的犬每月接受一次来自两名健康供体的同种异体 ASC 的血管内注射,共 11 个月。为了评估 ASC 的治疗效果,进行了骨科检查和临床评估。使用 ELISA 分析测量了血浆中肿瘤坏死因子-α和白细胞介素-6 的细胞因子。

结果

尽管重复和长期给予同种异体 ASC,但没有免疫排斥反应或细胞毒性等副作用。在 ASC 治疗后,犬的骨科检查评分下降,犬的临床状况和主人的满意度都非常好。

结论

尽管 ASC 因其抗炎和免疫抑制功能而被认为是 RA 治疗的选择之一,但从未用于治疗犬的 RA。本报告描述了一例用同种异体 ASC 长期治疗犬 RA 的病例,该犬无不良反应,临床状况改善。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69cc/9346526/682406f21aea/jvs-23-e61-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验